Microglia have critical roles not only in neural development and homeostasis, but also in neurodegenerative and neuroinflammatory diseases of the central nervous system [1] [2] [3] [4] . These highly diverse and specialized functions may be executed by subsets of microglia that already exist in situ, or by specific subsets of microglia that develop from a homogeneous pool of cells on demand. However, little is known about the presence of spatially and temporally restricted subclasses of microglia in the central nervous system during development or disease. Here we combine massively parallel singlecell analysis, single-molecule fluorescence in situ hybridization, advanced immunohistochemistry and computational modelling to comprehensively characterize subclasses of microglia in multiple regions of the central nervous system during development and disease. Single-cell analysis of tissues of the central nervous system during homeostasis in mice revealed specific time-and region-dependent subtypes of microglia. Demyelinating and neurodegenerative diseases evoked context-dependent subtypes of microglia with distinct molecular hallmarks and diverse cellular kinetics. Corresponding clusters of microglia were also identified in healthy human brains, and the brains of patients with multiple sclerosis. Our data provide insights into the endogenous immune system of the central nervous system during development, homeostasis and disease, and may also provide new targets for the treatment of neurodegenerative and neuroinflammatory pathologies.
. To compare expression patterns during homeostasis to those under pathological conditions, microglia were also isolated from mice with neurodegenerative (facial nerve axotomy) and demyelinating (cuprizone) pathologies (Extended Data Fig. 1a) . Following quality control, data from a total of 3,826 single microglia were further analysed using the RaceID algorithm 12 and finally depicted in t-distributed stochastic neighbour embedding (t-SNE) plots (Extended Data Fig. 1b, d ). Unsupervised clustering gave rise to 13 distinct clusters, corresponding to the ten microglia clusters present during development (C1 to C10), as well as one cluster for neurodegeneration (C11) and two clusters for demyelination and remyelination (C12 and C13) (Extended Data Fig. 1c ).
To gain insight into the diversity of microglia during development, we first focused on microglia from non-diseased CNS tissue. The t-SNE plots displayed two main clouds that clearly segregate embryonic and postnatal microglia (Fig. 1a) . Unbiased clustering revealed the presence of ten major clusters (the C1 to C10 referred to above) with distinct transcriptional profiles (Fig. 1b, c) . Clusters C1 to C6 predominantly consisted of embryonic microglia, whereas the postnatal microglia constituted clusters C7 to C10 (Fig. 1a, b) . Notably, the embryonic clusters were differentially distributed across the four regions of the embryonic CNS (Fig. 1d, e) . Likewise, the postnatal clusters showed a variable distribution both spatially and temporally; for example, C10 was enriched in juvenile cortical and hippocampal microglia, and the minor cluster C7 was more prevalent in the cerebellum and corpus callosum of adult mice (Fig. 1d, e) . The relative proportion of clusters in the cerebellum did not change between the juvenile and the adult stages, which is in sharp contrast to what was observed in the cortex and hippocampus (Fig. 1d, e) . As compared to juvenile microglia, adult microglia showed a more homogenous distribution of each cluster across regions (Fig. 1d, e) . Together, these data suggest different subtypes of microglia with distinct gene expressional profiles exist over the course of development, with strong variation between different regions of the CNS that might reflect local specification.
Among the top differentially regulated genes during development were the microglial homeostatic genes Tmem119, Selplg and Slc2a5, which are highly expressed in postnatal microglia (Fig. 2a) . The expression of Malat1, a long non-coding RNA, also increased during development (Extended Data Fig. 2a, b) . In the embryonic clusters, the lysosome-related genes Ctsb (which encodes cathepsin B), Ctsd (which encodes cathepsin D) and Lamp1 (which encodes lysosomal-associated membrane protein 1) were strongly expressed in C1 and C2 microglia (Fig. 2b, Extended Data Fig. 2c ), which suggests that lysosomal activity is enhanced in these embryonic microglia. Expression of Apoe, which encodes the myeloid cell activation marker apolipoprotein E (APOE) 13 , was enriched in the C1, C4 and C5 clusters (Fig. 2b) . C6 microglia were characterized by high levels of expression of Tmsb4x, Eef1a1 and Rpl4
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+ microglia in the embryonic brains by triple immunofluorescence staining of the corresponding proteins (Fig. 2c) . These distinct embryonic subpopulations were not observed in the postnatal brains (Fig. 2c, d ). On the other hand, the postnatal C9 and C10 clusters were characterized by high levels of expression of Cst3-which encodes cystatin C (also known as cystatin 3, CST3), a cysteine proteinase inhibitor that is involved in neurodegenerative diseases of the CNS 1 -and Sparc (which encodes 'secreted protein acidic and rich in cysteine') ( Fig. 2e) . Immunostaining for CST3 and SPARC confirmed the presence of CST3
+ microglia in the postnatal brains, whereas this population was virtually absent from embryonic forebrains (Fig. 2f, g ). Expression of CST3 was also detectable in a subpopulation of ALDH1L1 + astrocytes in the adult brain (Extended Data Fig. 3 ). In the juvenile cortex, almost all microglia expressed CST3 and SPARC (Fig. 2f, g ), whereas the abundance of this subpopulation of microglia was slightly diminished in the adult cortex (Fig. 2g) . By contrast, the proportion of CST3
+ microglia did not change between the juvenile and adult cerebellum (Fig. 2g) , although the overall percentage of SPARC-expressing microglia was lower in the cerebellum than in cortex (Fig. 2g) . Taken together, our data identify markers of subsets of microglia and demonstrate the spatiotemporal and phenotypic diversity of these subsets during CNS development and homeostasis in the adult brain.
To determine whether CNS pathology is accompanied by the appearance of disease-specific populations of microglia, we compared a model of toxic demyelination (cuprizone treatment) with the classical model for neurodegeneration (unilateral facial nerve axotomy, FNX) (Extended Data Fig. 1a) . The blood-brain barrier remains intact in both models, and a loss of oligodendrocytes in the corpus callosum (with cuprizone treatment) or a remote neurodegeneration within the facial nucleus (with FNX) lead to local microglial activation without recruitment of circulating monocytes 14, 15 . The two models enabled us 
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to study microglial plasticity after withdrawal of cuprizone or during axonal regeneration (Extended Data Fig. 1a) .
On the t-SNE plot, homeostatic microglia were distributed uniformly in a major population, but cells that clustered separately were found three days after FNX (cluster C11), and in the five-week and ten-week cuprizone treatment groups (clusters C12 and C13) (Extended Data Fig. 4a-c) . The distinct C11 cluster of microglia-characterized by strong expression of Ctsc (which encodes cathepsin C)-was observed three days after FNX (Fig. 3a, b) , whereas microglia in mice 14 days after FNX clustered with the homeostatic microglia population. By contrast, demyelination induced long-lasting transcriptional changes that only slightly recovered at the ten-week time point (Fig. 3c) . Collectively, our data suggest that microglia are able to rapidly change their phenotype and gain a discrete context-and time-dependent signature.
Analysis of the disease-specific signatures in microglia revealed that the expression of Apoe, Axl, Igf1, Lyz2, Itgax, Gpnmb and Apoc1 were induced during both demyelination and remyelination (Fig. 3d,  Extended Data Fig. 5a ). Fam20c, Cst7, Ccl6, Fn1, Ank, Psat1 and Spp1 were enriched to variable degrees in C12 microglia (Fig. 3d , e, Extended Data Fig. 5b, c, e) , whereas the C13 cluster of microglia was characterized by high levels of expression of Cybb and the MHC class II genes Cd74, H2-Aa and H2-Ab1 (Fig. 3d (Fig. 3f, g ). Overall, our results suggest that unique microglia subpopulations, characterized by distinct signatures, emerge under defined disease conditions.
To extend our studies of microglial heterogeneity from mice to humans, we analysed 1,180 cortical microglia that were isolated from surgically resected human brain tissue without histological evidence of CNS pathology (hereafter referred to as 'healthy') (Supplementary Table. 1). Unbiased hierarchical clustering revealed four major clusters, hereafter referred to as healthy human clusters 1 to 4 (HHu-C1 to HHu-C4) (Extended Data Fig. 6 ). Detailed analysis of differentially regulated genes revealed similarities with the gene expression profiles of mouse homeostatic microglia. For example, CST3 (which is enriched in mouse C9 and C10) was more highly expressed in HHu-C1 and HHu-C2 than in HHu-C3 and HHu-C4 (Extended Data Fig. 6f ). By contrast, the HHu-C4 cluster showed comparatively high levels of expression of the chemokine genes CCL4 and CCL2, and the zinc finger transcription factors EGR2 and EGR3 (Extended Data Fig. 6f ). Ccl4 mRNA was rarely expressed in mouse microglia even after cuprizone treatment (Extended Data Fig. 5j ). Notably, P2RY13 mRNA was highly expressed by the HHu-C1 and HHu-C2 clusters (Extended Data Fig. 6f ). Our analysis identified homeostatic human microglia states that have distinct gene expression patterns that partially overlap with those of adult mouse microglia. 
Activated microglia have previously been implicated in the disease progression of multiple sclerosis, a debilitating neurological disorder that is associated with demyelination 16 . To examine the presence of subpopulations of human microglia specific to multiple sclerosis, 422 CD45 + cells isolated from the brains of five patients with histologically confirmed early active multiple sclerosis (Extended Data Fig. 7 ) were subjected to scRNA-seq and subsequently analysed together with healthy human microglia ( Fig. 4a-d) . Unsupervised clustering grouped the CD45 + cells into ten clusters, which we termed human clusters 1 to 10 (Hu-C1 to Hu-C10) (Fig. 4a-d) . Among them, the transcriptome of the Hu-C1 showed a lymphocyte signature (Extended Data Fig. 8a) , and the Hu-C9 and Hu-C10 clusters were characterized by a clear monocytic profile (Extended Data Fig. 8a) ; these clusters were therefore excluded from further analysis. The remaining seven myeloid clusters (Hu-C2 to Hu-C8) expressed microglial core genes, such as TMEM119 and P2RY12, to varying degrees (Fig. 4d) . The Hu-C5, Hu-C6 and Hu-C7 clusters, which consisted entirely of microglia from healthy brains, showed the highest levels of expression of the microglial core genes and were therefore considered to represent homeostatic states of microglia (Fig. 4b-d, Extended  Data Fig. 8b ). The Hu-C4 cluster-which contained microglia from the healthy and diseased brains-was characterized by reduced levels of expression of the core signature genes, but elevated levels of CCL2, CCL4, EGR2 and other chemokine and cytokine genes, which suggests that these microglia were pre-activated (Fig. 4d, Extended Data Fig. 8e ). Two clusters of microglia that were enriched in brains of patients with multiple sclerosis (Hu-C3 and Hu-C8), and one cluster of microglia that was associated with multiple sclerosis (Hu-C2), were clearly separated from the homeostatic clouds on t-SNE plots (Fig. 4b-d) . The Hu-C2, Hu-C3 and Hu-C8 clusters showed an increased level of expression of APOE and MAFB (Extended Data Fig. 8g ), whereas the expression of microglial core genes was downregulated or even absent (Fig. 4d) . The strong reduction of TMEM119 expression in microglia in demyelinating lesions of brains from patients with multiple sclerosis was confirmed histologically (Extended Data Fig. 8i ). The Hu-C2 cluster was characterized by high levels of expression of CTSD, APOC1, GPNMB, ANXA2 and LGALS1 (Fig. 4d, Extended Data Fig. 8c ). Hu-C3 microglia showed increased gene expression of MHC class II-related molecules, such as CD74, HLA-DRA, HLA-DRB1 and HLA-DPB1 (Fig. 4d, Extended  Data Fig. 8d ). This suggests an immunoregulatory role, reminiscent of the subtype (C13) of microglia associated with remyelination in mice Letter reSeArCH (Fig. 3) . Finally, Hu-C8 microglia showed strong expression of SPP1, PADI2 and LPL genes, similar to the C12 microglia associated with demyelination in mice (Fig. 4d, Extended Data Fig. 8f ). Of note, canonical correlation analysis of mouse and human microglia orthologues confirmed that clusters of microglia (Hu-C2, Hu-C3 and Hu-C8) that are enriched in or associated with the brains of patients with multiple sclerosis have a gene expression profile that is similar to that of clusters of microglia associated with demyelination (C12) and remyelination (C13) in mice (Extended Data Fig. 9 ).
To validate our scRNA-seq results histologically, we first stained brain sections from patients with multiple sclerosis for MRP14, which is known to label infiltrating monocytes but not microglia in early active lesions 17 . Human brain sections without CNS pathology were virtually devoid of MRP14 +
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+ cells, whereas approximately 12% of IBA1 + cells in the brain sections from patients with multiple sclerosis were infiltrating monocytes (Extended Data Fig. 8j) (Fig. 4e, f) . In contrast to the mouse cuprizone-induced demyelination model, the proportion of SPP1-, CTSD-and CD74-expressing subsets of microglia varied substantially between individual patients with multiple sclerosis (Fig. 4e, f) , which indicates high inter-individual heterogeneity. Together, these findings suggest the existence of distinct disease-related subtypes of microglia in the brains of patients with multiple sclerosis, and that these microglia are phenotypically similar to subtypes of mouse microglia in a demyelination model.
Previous studies of regional variations in mice of microglial density 18 , surface expression of a small panel of immune molecules 19 , dependency on interleukin-34 20, 21 , electrophysiological features 22 , phagocytic activity 23 and microarray analysis of microglial bulk RNA 11 or scR-NA-seq 24 have suggested diversity of microglia. To our knowledge, our study provides the first in vivo comparison of microglia heterogeneity at a single-cell resolution in the mouse and human CNS (Extended Data  Fig. 10 ). Although we detected transcriptionally distinguishable subpopulations of microglia during homeostasis, these did not appear as distinct clusters but rather as a transcriptional continuum of the local population of microglia. This might reflect the transcriptional basis for the ability of microglia to swiftly adapt to changing environmental cues. Our data further indicate that microglial responses to pathology are not uniform, but are shaped by the underlying pathology. Specifically, we found disease-associated subtypes of microglia that differed between neurodegenerative conditions and toxic demyelination. The appearance of context-dependent subtypes of microglia with their own specific transcriptional profiles has the potential to reveal new therapeutic targets. Moreover, by establishing the transcriptional profile of heterogeneous populations of microglia in healthy and diseased rodents and humans, our study may provide insights into the pathogenesis of CNS diseases.
Online content
Any methods, additional references, Nature Research reporting summaries, source data, statements of data availability and associated accession codes are available at https://doi.org/10.1038/s41586-019-0924-x.
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MEthodS
No statistical methods were used to predetermine sample size. The experiments were not randomized and investigators were not blinded to allocation during experiments and outcome assessment. Mice. CD-1 mice were used. All animal experiments were approved by local administration and were performed in accordance to the respective national, federal and institutional regulations. Detailed mouse information is provided in Supplementary Table 1 . scRNA-seq for mouse microglia. Microglia were FACS-sorted from up to six different regions of the CNS of healthy and diseased brains (see gating strategy shown in Supplementary Fig. 1 ) into a 384-well plate containing a lysis buffer, and were analysed using the Smart-seq2 method. Expression profiles were obtained as absolute cDNA molecule counts using the STAR aligner 25 to align raw sequences in conjunction with feature Counts (part of the subread package) 26 to obtain gene counts. Further analysis and data normalization was performed using the RaceID package 12 . Clusters with more than ten individual cells were retained for further analysis, and normalized to transcripts per million to compensate for differences in total transcriptome size between cell types. Heat maps were generated using online software 27 . Analysis of microglia from human brains. All experiments with human materials were approved by the local administration and were performed in accordance with the respective national, federal and institutional regulations. Human microglia were isolated from histologically healthy brain tissue removed during brain surgery for the treatment of epilepsy in five individuals (these tissues are not part of the epileptic region but are routinely removed to surgically access the epileptic lesion). Histopathological changes were excluded by an experienced neuropathologist, and only histologically healthy specimens were included in this study. CD45
+ cells including microglia were FACS-sorted into a 384-well plate containing lysis buffer. scRNA-seq was conducted using the Cel-Seq2 protocol and processed as previously described 28 . Libraries were sequenced on an Illumina HiSeq 3000 System in high-output run mode at a depth of ~200,000 reads per cell. Paired-end reads were aligned to the transcriptome using bwa with default parameters, and all isoforms of the gene were counted to a single gene locus 29 . Reads that were not uniquely mapped were discarded. The left read contained the barcode information (6 bases corresponding to unique molecular identifier (UMI) plus 6 bases that represented the cell-specific barcode and a polyT stretch), and was omitted from quantification. The corresponding right read was mapped to the ensemble of all gene loci and used for quantification. Genes were counted on the basis of the number of UMIs per transcript from a given gene locus. The number of UMIs was converted to transcript counts based on a negative binomial distribution 30 . The aggregate of transcript counts with the same cell barcode represented the transcriptome of an individual cell. Data analysis, normalization and visualization was performed using the RaceID2 package 31 . Clusters with more than 15 individual cells were retained for further analysis and transcript counts were normalized by down sampling to 1,500. Detailed human patient information is provided in Supplementary Table 1 . Flow cytometry. After transcardial perfusion with PBS, brains were roughly minced and homogenized with a potter in HBSS containing 15 mM HEPES buffer and 0.54% glucose. Whole-brain homogenate was separated by 70/37/30% layered Percoll gradient centrifugation at 800g for 30 min at 4 °C (no brake). The CNS macrophages containing interphase were then collected and washed once with PBS containing 2% FCS and 10 mM EDTA before staining. Cells were stained with primary antibodies directed against CD11b (M1/70, BioLegend), CD45 (30-F11, BD Biosciences), Ly6C (AL-21, BD Biosciences) and Ly6G (1A8, BD Biosciences) for 20 min, and CD206 (C068C2, BioLegend) for 45 min at 4 °C. After washing, cells were sorted using a MoFlo Astrios (Beckman Coulter). Viable cells were gated by staining with Fixable Viability Dye (eBioscience). Data were acquired with Summit software (Becton Dickinson). Post-acquisition analysis was performed using FlowJo software, version X.0.7. Immunohistochemistry and cell quantifications. For juvenile and adult mice, after transcardial perfusion with PBS, brains were fixed for 4 h in 4% PFA, dehydrated in 30% sucrose and embedded in Tissue-Tek O.C.T. compound (Sakura Finetek Germany GmbH). For embryos, isolated brains were fixed for 4 h in 4% PFA, dehydrated in 30% sucrose and embedded in Tissue-Tek O.C.T. compound. Cryosections were obtained as previously described 32 . Sections were then blocked with PBS containing 5% bovine serum albumin and permeabilized with 0.1% Triton-X 100 in blocking solution. Primary antibodies were added over night at a 
were fixed in 4% PFA overnight and embedded in paraffin. Sections were then blocked with PBS containing 5% bovine serum albumin and permeabilized with 0.1% Triton-X 100 in blocking solution. Primary antibodies were treated over night at a dilution of 1:500 for IBA1 (ab178846, Abcam; ab139590, Abcam; NB100-1028, Novus Biologicals), 1:200 for SPP1 (HPA027541, Sigma), 1:500 for CD74 (ab9514, Abcam), 1:500 for CTSD (ab6313, Abcam) and 1:200 for MRP14 (T-1026, BMA Biomedicals; LS-B12844, LSBio). Secondary antibodies were purchased from Thermo Fisher Scientific added as follows: Alexa Fluor 405 1:500, Alexa Fluor 488 1:500, Alexa Fluor 568 1:500 and Alexa Fluor 647 1:500 for 2 h, at room temperature. Coverslips were mounted with/without ProLong Diamond Antifade Mountant with DAPI (Thermo Fisher Scientific). Images were taken using a conventional fluorescence microscope (Olympus BX-61 with a colour camera (Olympus DP71) or BZ-9000 (Keyence)) and the confocal pictures were taken with Fluoview FV 1000 (Olympus) using a 20 × 0.95 NA (XLUMPlanFL N, Olympus). Facial nerve axotomy and cuprizone model of demyelination and remyelination. Facial nerve was injured as previously described 14, 15 . In brief, mice were anaesthetized by subcutaneous injection of a mixture of ketamine (50 mg/kg) and xylazine (7.5 mg/kg), and the right facial nerve was transected at the stylomastoid foramen, resulting in ipsilateral whisker paresis. Cuprizone treatment was used as a model of toxic demyelination and remyelination 15, 33 . For demyelination, mice were fed for 5 weeks with 0.45% (wt/wt) cuprizone (Sigma) in the ground breeder chow. For remyelination, the cuprizone diet was discontinued after five weeks and animals were maintained for further five weeks under normal diet to allow spontaneous remyelination. Untreated age-matched mice were used as control. Single-molecule fluorescent in situ hybridization. Mice were perfused with PBS, followed by 4% paraformaldehyde (PFA). The brain tissues were collected and immersion-fixed in 4% PFA for 3 h, and subsequently were put into 30% sucrose in 4% PFA at 4 °C overnight, and embedded in OCT for sectioning, frozen on dry ice and stored at −80 °C until used. Ten-micrometre-thick sections mounted on the glass plate were washed 3 times with PBS, and treated with pre-chilled methanol for 10 min at −20 °C. Then, the slides were incubated for 10 min at 70 °C in Tris-EDTA (pH 8.0), and the sections were washed with SSC 2× and incubated for 4 h with hybridization buffer containing 250 nM fluorescent label probes (LGC Biosearch Technologies) at 38.5 °C. After 4 washes with 20% formamide wash buffer containing SSC 2×, the slides were mounted with Prolong Gold containing DAPI. Stack images were taken using a Olympus BX-61 microscope. Canonical correlation analysis. Comparisons between human and mouse data were performed by initially determining differentially expressed genes with RaceID by testing for differences between individual clusters versus all other steady-state or disease associated clusters. Genes found to be differentially expressed by in any of these comparisons (adjusted P < 0.01, fold change (expressed in log 2 ) > 1) were selected for further analysis. For genes from the human dataset, mouse orthologues were identified from the NCBI HomoloGene database (https://www.ncbi.nlm.nih. gov/homologene) using the annotationTools R package 34 ; the same was done to identify human orthologues for the mouse genes. All human genes with an orthologue in the mouse set, as well as all mouse genes with an orthologue in the human set, were kept. Canonical cluster analysis as implemented in the Seurat package 35 was then performed on the 768 common genes identified in this manner. Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Data availability
Raw data for mouse and human single cell RNA-sequencing have been deposited in the Gene Expression Omnibus, and are available at the following accession numbers: GSE120629 (mouse), GSE120747 (mouse) and GSE124335 (human). All other data are available from the corresponding author on reasonable request. The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Validation
All antibodies used were validated for use in FACS or histological analysis with mouse or human samples, which are shown on the website provided by respective companies.
Animals and other organisms
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research
Laboratory animals
Mouse (CD1 females at the age of 3 weeks and 16 weeks, CD1 embryos at the age of embryonic E16.5 days)
Wild animals
This study did not involve wild animals.
Field-collected samples
This study did not involve samples collected from the field.
Ethics oversight
The ethics board of the universities of Freiburg and Göttingen, Charité Universitätsmedizin Berlin approved of all experiments.
Note that full information on the approval of the study protocol must also be provided in the manuscript.
Human research participants
Policy information about studies involving human research participants
Population characteristics
All information for human material is provided in Supplementary Table 1.
Recruitment
Patients were prospectively recruited.
Ethics oversight
The institutional review boards of the universities of Freiburg and Essen approved of all experiments and informed consent was obtained from the human subjects prior to inclusion in the study.
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Methodology Sample preparation
For mouse, after transcardial perfusion with PBS, brains were roughly minced and homogenized with a potter in HBSS containing 15 mM HEPES buffer and 0.54 % Glucose. Whole-brain homogenate was separated by 70/37/30 % layered Percoll gradient centrifugation at 800 g for 30 min at 4 °C (no brake). The CNS macrophages containing interphase was then collected and washed once with PBS containing 2% FCS and 10mM EDTA before staining. Cells were stained with primary antibodies directed against CD11b (M1/70, BioLegend), CD45 (30-F11, BD Biosciences), Ly6C (AL-21, BD Biosciences) and Ly6G (1A8, BD Biosciences) for 20 min, and CD206 (C068C2, BioLegend) for 45 min at 4 °C. For human, brain blocks were roughly minced and homogenized with a potter in HBSS containing 15 mM HEPES buffer and 0.54 % Glucose. Whole-brain homogenate was separated by 37 % Percoll centrifugation at 800 g for 30 min at 4 °C (no brake). The pelet containing CNS macrophages was then collected and washed once with PBS containing 2% FCS and 10mM EDTA before staining. Cells were stained with primary antibodies directed against CD45 (, BD Biosciences) for 20 min at 4 °C.
Instrument
MoFlo Astrios (Beckman Coulter) for sorting Software Data were acquired with Summit software version6.3.0.16900 (Becton Dickinson). Postacquisition analysis was performed using FlowJo software, version X.0.7
